Do analysts recommend HIT or KINS?

Health In Tech currently has a consensus price target of $3.25, indicating a potential upside of 229.28%. Given Health In Tech's stronger consensus rating and higher possible upside, equities analysts clearly believe Health In Tech is more favorable than Kingstone Companies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Health In Tech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00 Kingstone Companies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend HIT or RDZN?

Health In Tech presently has a consensus target price of $3.25, indicating a potential upside of 229.28%. Given Health In Tech's stronger consensus rating and higher probable upside, analysts plainly believe Health In Tech is more favorable than Roadzen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Health In Tech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 2 Strong Buy rating(s) 3.00 Roadzen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HIT or RDZN more profitable?

Health In Tech has a net margin of 0.00% compared to Roadzen's net margin of -30.61%. Company Net Margins Return on Equity Return on Assets Health In Tech N/A N/A N/A Roadzen -30.61% N/A -40.70%

Health In Tech (HIT) Competitors

$0.99 -0.01 (-1.30%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$0.97 -0.02 (-1.72%)

As of 06/5/2026 07:24 PM Eastern

Compare

HIT vs. OSG, KINS, JRVR, SLQT, and RDZN

Should you buy Health In Tech stock or one of its competitors? MarketBeat compares Health In Tech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Health In Tech include Octave Specialty Group (OSG), Kingstone Companies (KINS), James River Group (JRVR), SelectQuote (SLQT), and Roadzen (RDZN). These companies are all part of the "insurance" industry.

How does Health In Tech compare to Octave Specialty Group?

Octave Specialty Group (NYSE:OSG) and Health In Tech (NASDAQ:HIT) are both small-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

80.9% of Octave Specialty Group shares are owned by institutional investors. 7.2% of Octave Specialty Group shares are owned by insiders. Comparatively, 77.7% of Health In Tech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Octave Specialty Group currently has a consensus target price of $15.00, indicating a potential upside of 173.47%. Health In Tech has a consensus target price of $3.25, indicating a potential upside of 229.28%. Given Health In Tech's stronger consensus rating and higher possible upside, analysts plainly believe Health In Tech is more favorable than Octave Specialty Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Octave Specialty Group	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Health In Tech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00

Health In Tech has lower revenue, but higher earnings than Octave Specialty Group. Health In Tech is trading at a lower price-to-earnings ratio than Octave Specialty Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Octave Specialty Group	$251.22M	0.98	-$261.69M	-$4.86	N/A
Health In Tech	$34.08M	1.90	-$1.31M	-$0.02	N/A

Octave Specialty Group has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Health In Tech has a beta of 2.93, meaning that its share price is 193% more volatile than the broader market.

Health In Tech has a net margin of 0.00% compared to Octave Specialty Group's net margin of -75.91%. Health In Tech's return on equity of 0.00% beat Octave Specialty Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Octave Specialty Group	-75.91%	-0.55%	-0.13%
Health In Tech	N/A	N/A	N/A

In the previous week, Octave Specialty Group's average media sentiment score of 0.00 equaled Health In Tech'saverage media sentiment score.

Company	Overall Sentiment
Octave Specialty Group	Neutral
Health In Tech	Neutral

Summary

Health In Tech beats Octave Specialty Group on 11 of the 15 factors compared between the two stocks.

How does Health In Tech compare to Kingstone Companies?

Health In Tech (NASDAQ:HIT) and Kingstone Companies (NASDAQ:KINS) are both small-cap finance companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Kingstone Companies has a net margin of 13.86% compared to Health In Tech's net margin of 0.00%. Kingstone Companies' return on equity of 28.63% beat Health In Tech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health In Tech	N/A	N/A	N/A
Kingstone Companies	13.86%	28.63%	7.23%

Health In Tech currently has a consensus price target of $3.25, indicating a potential upside of 229.28%. Given Health In Tech's stronger consensus rating and higher possible upside, equities analysts clearly believe Health In Tech is more favorable than Kingstone Companies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health In Tech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kingstone Companies	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

14.9% of Kingstone Companies shares are owned by institutional investors. 77.7% of Health In Tech shares are owned by insiders. Comparatively, 5.1% of Kingstone Companies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Kingstone Companies has higher revenue and earnings than Health In Tech. Health In Tech is trading at a lower price-to-earnings ratio than Kingstone Companies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health In Tech	$34.08M	1.90	-$1.31M	-$0.02	N/A
Kingstone Companies	$214.87M	1.04	$40.77M	$2.15	7.18

Health In Tech has a beta of 2.93, suggesting that its share price is 193% more volatile than the broader market. Comparatively, Kingstone Companies has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

In the previous week, Kingstone Companies had 4 more articles in the media than Health In Tech. MarketBeat recorded 4 mentions for Kingstone Companies and 0 mentions for Health In Tech. Kingstone Companies' average media sentiment score of 1.56 beat Health In Tech's score of 0.00 indicating that Kingstone Companies is being referred to more favorably in the news media.

Company	Overall Sentiment
Health In Tech	Neutral
Kingstone Companies	Very Positive

Summary

Kingstone Companies beats Health In Tech on 10 of the 16 factors compared between the two stocks.

How does Health In Tech compare to James River Group?

Health In Tech (NASDAQ:HIT) and James River Group (NASDAQ:JRVR) are both small-cap finance companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

Health In Tech presently has a consensus price target of $3.25, indicating a potential upside of 229.28%. James River Group has a consensus price target of $6.44, indicating a potential upside of 62.56%. Given Health In Tech's stronger consensus rating and higher possible upside, research analysts plainly believe Health In Tech is more favorable than James River Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health In Tech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
James River Group	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

In the previous week, James River Group had 1 more articles in the media than Health In Tech. MarketBeat recorded 1 mentions for James River Group and 0 mentions for Health In Tech. Health In Tech's average media sentiment score of 0.00 beat James River Group's score of -0.35 indicating that Health In Tech is being referred to more favorably in the media.

Company	Overall Sentiment
Health In Tech	Neutral
James River Group	Neutral

James River Group has higher revenue and earnings than Health In Tech. Health In Tech is trading at a lower price-to-earnings ratio than James River Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health In Tech	$34.08M	1.90	-$1.31M	-$0.02	N/A
James River Group	$687.61M	0.27	$47.43M	$0.34	11.65

James River Group has a net margin of 4.34% compared to Health In Tech's net margin of 0.00%. James River Group's return on equity of 10.79% beat Health In Tech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health In Tech	N/A	N/A	N/A
James River Group	4.34%	10.79%	1.13%

Health In Tech has a beta of 2.93, suggesting that its share price is 193% more volatile than the broader market. Comparatively, James River Group has a beta of -0.16, suggesting that its share price is 116% less volatile than the broader market.

95.2% of James River Group shares are owned by institutional investors. 77.7% of Health In Tech shares are owned by insiders. Comparatively, 33.8% of James River Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

James River Group beats Health In Tech on 9 of the 16 factors compared between the two stocks.

How does Health In Tech compare to SelectQuote?

Health In Tech (NASDAQ:HIT) and SelectQuote (NYSE:SLQT) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment.

SelectQuote has higher revenue and earnings than Health In Tech. Health In Tech is trading at a lower price-to-earnings ratio than SelectQuote, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health In Tech	$34.08M	1.90	-$1.31M	-$0.02	N/A
SelectQuote	$1.53B	0.10	$47.58M	$0.09	9.72

SelectQuote has a net margin of 5.60% compared to Health In Tech's net margin of 0.00%. SelectQuote's return on equity of 20.49% beat Health In Tech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Health In Tech	N/A	N/A	N/A
SelectQuote	5.60%	20.49%	5.58%

34.6% of SelectQuote shares are owned by institutional investors. 77.7% of Health In Tech shares are owned by company insiders. Comparatively, 13.1% of SelectQuote shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Health In Tech currently has a consensus target price of $3.25, indicating a potential upside of 229.28%. SelectQuote has a consensus target price of $3.00, indicating a potential upside of 242.86%. Given SelectQuote's higher probable upside, analysts clearly believe SelectQuote is more favorable than Health In Tech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health In Tech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
SelectQuote	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

Health In Tech has a beta of 2.93, suggesting that its stock price is 193% more volatile than the broader market. Comparatively, SelectQuote has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

In the previous week, Health In Tech's average media sentiment score of 0.00 equaled SelectQuote'saverage media sentiment score.

Company	Overall Sentiment
Health In Tech	Neutral
SelectQuote	Neutral

Summary

SelectQuote beats Health In Tech on 9 of the 13 factors compared between the two stocks.

How does Health In Tech compare to Roadzen?

Health In Tech (NASDAQ:HIT) and Roadzen (NASDAQ:RDZN) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

Health In Tech has a beta of 2.93, suggesting that its stock price is 193% more volatile than the broader market. Comparatively, Roadzen has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

In the previous week, Health In Tech's average media sentiment score of 0.00 equaled Roadzen'saverage media sentiment score.

Company	Overall Sentiment
Health In Tech	Neutral
Roadzen	Neutral

Health In Tech has higher earnings, but lower revenue than Roadzen. Health In Tech is trading at a lower price-to-earnings ratio than Roadzen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health In Tech	$34.08M	1.90	-$1.31M	-$0.02	N/A
Roadzen	$44.30M	3.08	-$72.87M	-$0.20	N/A

Health In Tech has a net margin of 0.00% compared to Roadzen's net margin of -30.61%.

Company	Net Margins	Return on Equity	Return on Assets
Health In Tech	N/A	N/A	N/A
Roadzen	-30.61%	N/A	-40.70%

Health In Tech presently has a consensus target price of $3.25, indicating a potential upside of 229.28%. Given Health In Tech's stronger consensus rating and higher probable upside, analysts plainly believe Health In Tech is more favorable than Roadzen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health In Tech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Roadzen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

24.7% of Roadzen shares are owned by institutional investors. 77.7% of Health In Tech shares are owned by insiders. Comparatively, 29.5% of Roadzen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Health In Tech beats Roadzen on 9 of the 13 factors compared between the two stocks.

Get Health In Tech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HIT vs. The Competition

Export

Metric	Health In Tech	Insurance Agents, Brokers & Service Industry	Finance Sector	NASDAQ Exchange
Market Cap	$65.53M	$1.21B	$13.56B	$11.99B
Dividend Yield	N/A	N/A	5.80%	5.55%
P/E Ratio	-49.35	47.31	19.92	23.63
Price / Sales	1.90	8.04	137.56	112.20
Price / Cash	N/A	57.47	19.15	54.60
Price / Book	N/A	0.65	2.18	6.35
Net Income	-$1.31M	$17.47M	$1.13B	$337.59M
7 Day Performance	-0.51%	-7.24%	-0.31%	-2.52%
1 Month Performance	-37.13%	-19.45%	-0.61%	-0.03%
1 Year Performance	56.69%	12.17%	10.77%	25.34%

Health In Tech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HIT Health In Tech	3.0697 of 5 stars	$0.99 -1.3%	$3.25 +229.3%	+56.7%	$65.53M	$34.08M	N/A	79
OSG Octave Specialty Group	3.8835 of 5 stars	$5.50 -0.5%	$15.00 +173.0%	N/A	$246.68M	$251.22M	N/A	130	Analyst Downgrade
KINS Kingstone Companies	3.9396 of 5 stars	$14.87 -3.1%	N/A	+1.3%	$215.39M	$214.87M	6.92	90	Positive News
JRVR James River Group	4.643 of 5 stars	$3.91 -0.8%	$6.44 +64.6%	-33.2%	$180.79M	$687.61M	11.50	640	Analyst Downgrade
SLQT SelectQuote	3.9825 of 5 stars	$1.01 -5.2%	$3.00 +198.5%	-60.2%	$176.35M	$1.53B	11.17	4,269

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HIT) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Health In Tech (HIT) Competitors

HIT vs. OSG, KINS, JRVR, SLQT, and RDZN

How does Health In Tech compare to Octave Specialty Group?

Summary

How does Health In Tech compare to Kingstone Companies?

Summary

How does Health In Tech compare to James River Group?

Summary

How does Health In Tech compare to SelectQuote?

Summary

How does Health In Tech compare to Roadzen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIT vs. The Competition

Health In Tech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Health In Tech (HIT) Competitors

HIT vs. OSG, KINS, JRVR, SLQT, and RDZN

How does Health In Tech compare to Octave Specialty Group?

Do insiders & institutionals have more ownership in OSG or HIT?

Do analysts recommend OSG or HIT?

Which has preferable valuation & earnings, OSG or HIT?

Which has more risk & volatility, OSG or HIT?

Is OSG or HIT more profitable?

Does the media refer more to OSG or HIT?

Summary

How does Health In Tech compare to Kingstone Companies?

Is HIT or KINS more profitable?

Do analysts recommend HIT or KINS?

Do insiders and institutionals believe in HIT or KINS?

Which has higher earnings and valuation, HIT or KINS?

Which has more volatility & risk, HIT or KINS?

Does the media favor HIT or KINS?

Summary

How does Health In Tech compare to James River Group?

Do analysts rate HIT or JRVR?

Does the media prefer HIT or JRVR?

Which has higher valuation and earnings, HIT or JRVR?

Is HIT or JRVR more profitable?

Which has more volatility and risk, HIT or JRVR?

Do insiders & institutionals have more ownership in HIT or JRVR?

Summary

How does Health In Tech compare to SelectQuote?

Which has preferable earnings & valuation, HIT or SLQT?

Is HIT or SLQT more profitable?

Do institutionals and insiders have more ownership in HIT or SLQT?

Do analysts rate HIT or SLQT?

Which has more volatility & risk, HIT or SLQT?

Does the media prefer HIT or SLQT?

Summary

How does Health In Tech compare to Roadzen?

Which has more risk and volatility, HIT or RDZN?

Does the media prefer HIT or RDZN?

Which has stronger valuation & earnings, HIT or RDZN?

Is HIT or RDZN more profitable?

Do analysts recommend HIT or RDZN?

Do institutionals & insiders have more ownership in HIT or RDZN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HIT vs. The Competition

Health In Tech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools